Venom and Antivenom of the Redback Spider (Latrodectus hasseltii) in Japan(Part 2)Experimental Production of Equine Antivenom against the Redback Spider
-
- Mori Shigemi
- The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)
-
- Horita Akira
- The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)
-
- Ginnaga Akihiro
- The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)
-
- Miyatsu Yoshinobu
- The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)
-
- Sawabe Kyoko
- National Institute of Infectious Diseases
-
- Matsumura Takayuki
- National Institute of Infectious Diseases
-
- Ato Manabu
- National Institute of Infectious Diseases
-
- Yamamoto Akihiko
- National Institute of Infectious Diseases
-
- Shibayama Keigo
- National Institute of Infectious Diseases
-
- Arai Satoru
- National Institute of Infectious Diseases
-
- Yamagishi Takuya
- National Institute of Infectious Diseases
-
- Takahashi Motohide
- Pharmaceuticals and Medical Devices Agency
-
- Taki Hisashi
- Ministry of Health, Labour and Welfare
-
- Hifumi Toru
- Kagawa University Hospital Emergency Medical Center
書誌事項
- タイトル別名
-
- Venom and Antivenom of the Redback Spider (<i>Latrodectus hasseltii</i>) in Japan. Part II. Experimental Production of Equine Antivenom against the Redback Spider
この論文をさがす
抄録
<p>This is the first report on large-scale experimental production of an equine antivenom against the redback spider (Latrodectus hasseltii) lived in Japan. We captured 10,000 redback spiders in Japan and prepared the toxoids of crude venom extract, mixed the toxoids with a mineral oil adjuvant, and immunized healthy horses repeatedly over a period of several weeks. Thereafter, we separated the horse plasma, purified the γ-globulin fraction, and stocked it as a purified antivenom concentrate. Consequently, we manufactured approximately 6,500 vials of a single-dose freeze-dried test lot from a portion of the purified γ-globulin fraction, equivalent to the extract derived from 520 spiders. This test lot had an antitoxin titer comparable to that of a similar drug commercially available overseas (a liquid preparation), and the other quality met all quality reference specifications based on the Minimum Requirements for Biological Products and other guidelines relevant to existing antivenom drug products in Japan.</p>
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 70 (6), 635-641, 2017
国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206241206784
-
- NII論文ID
- 130006210304
-
- NII書誌ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL書誌ID
- 028691656
-
- PubMed
- 29093316
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可